Apex Biotechnology Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Apex Biotechnology.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Medical Equipment earnings growth | 20.6% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 16 Jul 2024 |
Recent future growth updates
Recent updates
Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around
Aug 06Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings
Mar 21Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business
Apr 17Is Apex Biotechnology (TPE:1733) Using Too Much Debt?
Mar 30Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?
Mar 10Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?
Feb 17A Look At Apex Biotechnology's (TPE:1733) Share Price Returns
Jan 27Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture
Jan 06These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely
Dec 16Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?
Nov 22In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Apex Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 1,891 | 105 | 271 | 291 | 1 |
6/30/2024 | 1,711 | 109 | 240 | 265 | N/A |
3/31/2024 | 1,691 | 109 | 294 | 315 | N/A |
12/31/2023 | 1,677 | 116 | 205 | 230 | N/A |
9/30/2023 | 1,775 | 144 | 95 | 121 | N/A |
6/30/2023 | 1,968 | 170 | 22 | 55 | N/A |
3/31/2023 | 2,159 | 172 | -13 | 20 | N/A |
12/31/2022 | 2,244 | 182 | -14 | 27 | N/A |
9/30/2022 | 2,297 | 220 | 25 | 72 | N/A |
6/30/2022 | 2,201 | 220 | 33 | 73 | N/A |
3/31/2022 | 2,077 | 214 | 16 | 54 | N/A |
12/31/2021 | 2,132 | 202 | 150 | 180 | N/A |
9/30/2021 | 2,025 | 154 | 284 | 311 | N/A |
6/30/2021 | 2,025 | 113 | 274 | 306 | N/A |
3/31/2021 | 2,070 | 117 | 298 | 340 | N/A |
12/31/2020 | 2,005 | 95 | 232 | 281 | N/A |
9/30/2020 | 2,217 | 143 | 276 | 333 | N/A |
6/30/2020 | 2,173 | 103 | 353 | 416 | N/A |
3/31/2020 | 2,186 | 104 | 269 | 324 | N/A |
12/31/2019 | 2,199 | 114 | 406 | 463 | N/A |
9/30/2019 | 2,052 | -4 | 137 | 207 | N/A |
6/30/2019 | 2,142 | 83 | 159 | 241 | N/A |
3/31/2019 | 2,098 | 100 | 136 | 216 | N/A |
12/31/2018 | 2,044 | 95 | -15 | 68 | N/A |
9/30/2018 | 1,996 | 177 | 92 | 150 | N/A |
6/30/2018 | 1,919 | 129 | 145 | 183 | N/A |
3/31/2018 | 1,841 | 142 | N/A | 164 | N/A |
12/31/2017 | 1,795 | 86 | N/A | 71 | N/A |
9/30/2017 | 1,692 | -90 | N/A | 96 | N/A |
6/30/2017 | 1,617 | -110 | N/A | 118 | N/A |
3/31/2017 | 1,706 | -103 | N/A | 165 | N/A |
12/31/2016 | 1,763 | 3 | N/A | 298 | N/A |
9/30/2016 | 1,874 | 209 | N/A | 436 | N/A |
6/30/2016 | 1,941 | 316 | N/A | 394 | N/A |
3/31/2016 | 1,855 | 292 | N/A | 423 | N/A |
12/31/2015 | 1,847 | 262 | N/A | 472 | N/A |
9/30/2015 | 1,863 | 271 | N/A | 455 | N/A |
6/30/2015 | 1,821 | 224 | N/A | 405 | N/A |
3/31/2015 | 1,840 | 248 | N/A | 340 | N/A |
12/31/2014 | 1,789 | 273 | N/A | 268 | N/A |
9/30/2014 | 1,648 | 220 | N/A | 218 | N/A |
6/30/2014 | 1,674 | 209 | N/A | 121 | N/A |
3/31/2014 | 1,728 | 307 | N/A | 305 | N/A |
12/31/2013 | 1,829 | 371 | N/A | 485 | N/A |
9/30/2013 | 1,957 | 469 | N/A | 482 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1733's forecast earnings growth is above the savings rate (1%).
Earnings vs Market: Insufficient data to determine if 1733's earnings are forecast to grow faster than the TW market
High Growth Earnings: Insufficient data to determine if 1733's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1733's revenue is forecast to grow faster than the TW market.
High Growth Revenue: Insufficient data to determine if 1733's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1733's Return on Equity is forecast to be high in 3 years time